



NAME 藍先元 Lane, Hsien-Yuan		POSITION TITLE Director Professor	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Taipei Medical College, Taipei	M.D.	1987	Medicine
Board Certified in Psychiatry		1992	
National Defense Medical College, Taipei	Ph.D.	2000	Life Sciences

CURRENT POSITIONS

Chief, Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
 Director, Institute of Clinical Medical Science, China Medical University Medical College, Taichung, Taiwan
 Professor, Institute of Clinical Medical Science, China Medical University Medical College, Taichung, Taiwan
 Adjunct Professor, Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University

RESEARCH INTEREST

Neuropsychopharmacology
 Pharmacogenomics
 Psychiatric genetics
 Cognitive neuroscience

HONORS

1996,1997,1998 Young Investigator Award, National Science Council, Taiwan
 1999, 2000 Senior Investigator Award, National Science Council, Taiwan
 2005 A-class Research Award, National Science Council, Taiwan (for 3 years)
 2005 Distinguished Investigators Award, China Medical University, Taiwan
 2006 Y.Z. Hsu Scientific Paper Award, Biotechnology Category, Taiwan
 2000, 2003, 2004, 2005, 2006, 2007
 Schizophrenia Research Award, Society of Psychiatry, Taiwan (since 2008, this award is limited to a maximum of 3 times)
 2007 Distinguished Research Paper Award, National Cheng Kung University Medical College, Taiwan
 2007 Distinguished Investigators Award, China Medical University, Taiwan (for 3 years)
 2008 Distinguished Research Paper Award, China Medical University, Taiwan

EDITORIAL BOARD

2004-2007, Psychiatry and Clinical Neuroscience
 2007-present, The Open Nitric Oxide Journal

REVIEWER

2004, Journal of Clinical Psychopharmacology (3 papers)
 2005, Prog Neuropsychopharmacol & Biol Psychiatry (2 papers)
 2005, Acta Pharmacologica Sinica
 2005, The Journal of Nutritional Biochemistry
 2005, Biological Psychiatry (2 papers)
 2006, World Journal of Biological Psychiatry
 2006, Journal of Formosan Medical Association (2 papers)
 2006, Chinese Journal of Physiology
 2006, Psychiatry Research
 2006, Journal of Clinical Psychopharmacology (3 papers)
 2006, Future Neurology
 2006, Journal of Affective Disorder

2007, Journal of Formosan Medical Association (2 papers)
 2007, BMC Psychiatry
 2007, Comprehensive Psychiatry
 2007, Human Psychopharmacology: Clinical and Experimental
 2007, Journal of Biomedical Science
 2007, World Journal of Biological Psychiatry
 2007, The Journal of Nutritional Biochemistry
 2007, The Pharmacogenomics Journal
 2007, Pharmacogenomics
 2007, Journal of Psychopharmacology
 2007, Biological Psychiatry (3 papers)
 2008, Journal of Psychiatry Research (2 papers)
 2008, Psychiatry Research
 2008, The Chinese Journal of Physiology
 2008, Lipids in Health and Disease
 2008, Journal of Formosan Medical Association (2 papers)
 2008, World Journal of Biological Psychiatry (2 papers)
 2008, Personalized Medicine
 2008, Expert Review of Neurotherapeutics
 2008, Pharmacogenomics
 2008, Journal of Clinical Psychopharmacology (2 papers)
 2008, Journal of Psychopharmacology
 2008, Schizophrenia Research
 2009, BMJ Case Reports
 2009, Journal of Formosan Medical Association
 2009, Journal of Clinical Psychopharmacology
 2009, Biological Psychiatry

PEER-REVIEWED PUBLICATIONS (SINCE 2004)

1. **Lane HY**, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH (2004): Risperidone response and 5-HT₆ receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. *Schizophrenia Research* 67:63-70 (sci)
2. Tsai G, **Lane HY***, Yang P, Chong MY, Lange N (2004): Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. *Biological Psychiatry* 55:452-456 (sci) **[*shared first author]**
3. **Lane HY**, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH (2004): Fine-tuning risperidone dosage for acute schizophrenia: clinical determinants *Psychopharmacology* 172:393-399 (sci)
4. Su KP, **Lane HY**, Chuang CL, Chen KP, Shen WW (2004): Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. *Schizophrenia Research* 66:191-192 (sci)
5. **Lane HY**, Huang CL, Lin CY, Chang WH (2004): NMDA modulation and schizophrenia. *Current Topics in Pharmacology* 8:305-312
6. Lu ML, **Lane HY***, Lin SK, Chen KP, Chang WH (2004): Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. *Journal of Clinical Psychiatry* 65: 766-771 (sci) **[*corresponding author]**
7. **Lane HY**, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004): Effects of dopamine D₂ receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. *International Journal of Neuropsychopharmacology* 7:461-470 (sci)
8. Liu YC, Huang CH, **Lane HY*** (2004): N-methyl-D-aspartate (NMDA) Hypothesis of Schizophrenia. *Taiwanese Journal of Psychiatry* 18: 172-180 **[*corresponding author]**
9. Chiu CC, **Lane HY**, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2004): Dose-dependent alternations in oral bioavailability and clearance of olanzapine during coadministration of fluvoxamine in schizophrenic patients. *Journal of Clinical Pharmacology* 44: 1385-1390 (sci)
10. **Lane HY**, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH (2005): Dopamine D₃ receptor Ser9Gly polymorphism and risperidone response: a rigorous pharmacogenetic study. *Journal of Clinical Psychopharmacology* 25:6-11 (sci)
11. Sun HS, Fann CSJ, **Lane HY**, Chang YT, Chang CJ, Liu YL, Cheng ATA (2005). A functional polymorphism in the promoter region of the tryptophan hydroxylase (TPH1) gene is associated with alcohol dependence in one aboriginal group in Taiwan. *Alcoholism: Clinical and Experimental Research* 29:1-7 (sci)

12. **Lane HY**, Lee CC, Liu YC, Chang WH (2005): Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. *Pharmacogenomics* 6:139-149 (sci)
13. Chiu CC, **Lane HY***, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2005): Regular-dose risperidone on QTc intervals. *Journal of Clinical Psychopharmacology* 25:391-393 (sci) [***corresponding author**]
14. Chen CM, **Lane HY***, Wu YR, Ro LS, Chen FL, Hung WL, Hou YT, Lin CY, Huang SY, Chen I C, Soong BW, Li ML, Hsieh-Li HM, Su MT, Lee-Chen GJ (2005): Expanded trinucleotide repeats in the TBP/SCA17 gene, but not the KLHL1AS/SCA8 and PPP2R2B/SCA12 genes, are associated with schizophrenia. *Schizophrenia Research* 78:131-136 (sci) [***corresponding author**]
15. **Lane HY**, Chang YC, Liu YC, Chiu CC, Tsai G (2005): Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. *Archives of General Psychiatry* 62:1196-1204 (sci)
16. Hsieh CL, Chang QY, Lin IH, Lin JG, Liu CH, Tang NY, **Lane HY*** (2006): The study of electroacupuncture on cerebral blood flow in rats with and without cerebral ischemia. *American Journal of Chinese Medicine* 34:351-361 (sci) [***corresponding author**]
17. **Lane HY**, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH (2006): Risperidone-related weight gain: genetic and nongenetic predictors. *Journal of Clinical Psychopharmacology* 26:128-134 (sci)
18. **Lane HY**, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G (2006): Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. *Biological Psychiatry* 60:645-649 (sci)
19. Loh EW, **Lane HY**, Chen CH, Chang PS, Ku LW, Wang KHZ, Cheng ATA (2006): Glutamate decarboxylase genes and alcoholism in Han Taiwanese men. *Alcoholism: Clinical and Experimental Research* 30:1817-1823 (sci)
20. Chang YC, **Lane HY**, Yang KH, Huang CL (2006): Optimizing early prediction for antipsychotic response in schizophrenia. *Journal of Clinical Psychopharmacology* 26:554-559 (sci)
21. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, **Lane HY*** (2007): Early prediction of clinical response in schizophrenia patients receiving atypical antipsychotic zotepine. *The Journal of Clinical Psychiatry* 68:1522-1527 (sci) [***corresponding author**]
22. **Lane HY**, Liu YC, Huang CL, Hsieh CL, Chang YL, Chang L, Chang YC, Chang WH (2008): Prefrontal executive function and D1, D3, 5-HT2A, and 5-HT6 receptors gene variations in healthy participants. *Journal of Psychiatry and Neuroscience* 33:47-53 (sci)
23. Lin CH, Lin KS, Lin CY, Chen MC, **Lane HY*** (2008): Time to rehospitalization in major depression patients taking venlafaxine or fluoxetine. *The Journal of Clinical Psychiatry* 69:54-59 (sci) [***corresponding author**]
24. Lin YC, Chen HZ, Chang TJ, **Lane HY*** (2008): Hypokalemia following rapid titration of quetiapine treatment. *The Journal of Clinical Psychiatry* 69:165-166 (sci) [***corresponding author**]
25. **Lane HY**, Liu YC, Huang CL, Chang YC, Wu PL, Huang CH, Tsai G (2008): RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. *Journal of Clinical Psychopharmacology* 28:64-68 (sci)
26. Tsai GE, **Lane HY***, VanDenBerg CM, Liu YC, Tsai P, Jann MW (2008): Disposition of D-serine in Healthy Adults. *The Journal of Clinical Pharmacology* 48:524-527 (sci) [***shared first author**]
27. **Lane HY**, Liu YC, Huang CL, Chang YC, Liao CH, Tsai G (2008): Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. *Biological Psychiatry* 63:9-12 (sci) (selected for the commentary article)
28. Ma WF, **Lane HY**, Laffrey SC (2008): A model testing factors that influence physical activity for Taiwanese adults with anxiety. *Research in Nursing and Health* Apr 7 [Epub ahead of print]
29. Chen CM, Hou YT, Liu JY, Wu YR, Lin CH, Fung HC, Hsu WC, Hsu Y, Lee SH, Hsieh-Li HM, Su MT, Chen ST, **Lane HY**, Lee-Chen GJ (2008): PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. *Am J Med Genet B Neuropsychiatr Genet.* 2008 May 15. [Epub ahead of print]
30. Lin CH, Huang CW, Chen CC, Hsu YF, Chang WH, **Lane HY*** (2008): Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics. *Psychopharmacology.* Jun 20. [Epub ahead of print] [***corresponding author**]
31. Lin YC, Su HK, Ouyang WC, **Lane HY*** (2008): Zotepine-Induced QTc prolongation. *Journal of Clinical Psychopharmacology* (in press) [***corresponding author**]
32. Chang JP, Tsai CH, Wu PL, **Lane HY**, Su KP (2009): Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression. *Prog Neuropsychopharmacol Biol Psychiatry.* 2009 Mar 26. [Epub ahead of print]
33. Liu YC, Huang CL, Wu PL, Chang YC, Huang CH, **Lane HY*** (2009): Lack of association between AKT1 variances vs. clinical manifestations and social function in patients with schizophrenia. *Journal of Psychopharmacology* [Epub ahead of print] [***corresponding author**]

34. Ma WF, Yen JW, Chen WC, Chang HJ, Huang XY, **Lane HY*** (2009): The roles of state and trait anxiety in physical activity participation for Taiwanese adults with anxiety disorders. J Formos Med Assoc. (Accepted) [*corresponding authors]
35. **Lane HY**, Huang CL, Chang YC, Lau CH, Wu PL, Chou A, Tsai G (2009): Increased DAOA (G72) mRNA expression in WBC of patients with schizophrenia: an NMDA diagnostic biomarker. Archives of General Psychiatry (revision under review). (sci)
36. Hsu HY, **Lane HY*** Association of emotion perception with DRD3 Ser9Gly polymorphism in schizophrenia patients (2009): Psychiatry Research (in revision) [*corresponding author]
37. **Lane HY**, Lin C-H, Huang CL, Chang YC, Liao CH, Tsai GE (2009): A Randomized, double-blind, placebo-controlled study of sarcosine (N-methylglycine) and D-serine add-on treatment for chronically stable schizophrenia. Neuropsychopharmacology (submitted)(sci)

PATENT

US Provisional Patent Application 61/028138: A diagnostic blood test for psychosis. Guochuan.E.Tsai and **Hsien.-Yuan Lane** are inventors.

RECENT RESEARCH SUPPORT

1. NARSAD #12537-01 Lane (Role: Co-PI) 9/16/06-9/15/08 NARSAD, USA
Evaluating sarcosine, a glycine uptake inhibitor, for cognition enhancement in schizophrenia
2. NSC-95-2314-B-006-118-MY3 Lane (Role: PI) 8/01/06-7/31/09 National Science Council, Taiwan
NMDA modulation in schizophrenia: long-term efficacy of glycine transporter I inhibitor
3. NSC-97-2314-B-039-006-MY3 Lane (Role: PI) 8/01/08-7/31/11 National Science Council, Taiwan
D-amino acid oxidase inhibition for NMDA modulation of schizophrenia
4. NHRI-EX-94-9134PI Lane (Role: PI) 1/01/05-12/31/09 National Health Research Institutes, Taiwan
NMDA hypofunction of schizophrenia: diagnosis and treatment